Patients with primary biliary cholangitis had a better prognosis and saw improvements in their GLOBE and UK-PBC scores when treated with bezafibrate and ursodeoxycholic acid monotherapy, according to a study by Akira Honda, MD, PhD, of Tokyo Medical University Ibaraki Medical Center in Japan and colleagues that was published in Hepatology. Bezafibrate is commonly used in Japan, and Western countries have also recognized its efficacy, Honda said.
PBC prognosis improves with bezafibrate-UDCA combination, study finds
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.